Vertex Pharmaceuticals 주식 (NASDAQ: VRTX)

에 대한 최신 뉴스 Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Indianapolis,-,Circa,November,2021:,Eli,Lilly,And,Company,World

Earnings

Equities

Large Cap

News

Movers

AFRM

ARGX

BNTX

DASH

MMYT

REGN

SMMT

VRTX

지난주 가장 저조한 성과를 기록한 대형주는 다음과 같다. 일라이 릴리, 어펌 홀딩스, 리제네론, 아겐스, 버텍스 파마슈티컬스, 서밋 테라퓨틱스, 메이크마이트립, 바이오엔테크, FNF, 오로라, 도어대시

일라이릴리·어펌홀딩스·리제네론 등 지난주 급락한 대형주 12종목 (5월 5일~9일)

wall street ai15

Education

Econ #s

2025년 1분기에 가장 성과가 좋았던 S&amp;P 500 주식 다섯 종목은 CVS 헬스(NYSE:CVS), 필립모리스(NYSE:PM), 뉴몬트(NYSE:NEM), 센코라(NYSE:COR), 그리고 버텍스 파마슈티컬스(NASDAQ:VRTX)이며, 이들은 최근 며칠 동안 단지 미미한 하락만 겪었다. 무역 긴장과 경기 침체에 대한 우려로 S&amp;P 500 지수가 10% 급락한 것과는 대조적이다. 

S&amp;P 500 종목 중 2025년 1분기에 강세 보인 5개 주식...랠리 지속될까?

McDonald's Launches Limited-Edition Holiday Cups Co-Branded With Doodles

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

VOXX

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

월요일 주목해야 할 주식: 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

The U.S. Food and Drug Administration (FDA) on Wednesday initiated <a href="https://www.fda.gov/news-events/press-announcements/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic">an immediate review</a> of clinical trials that involved sending Americans&#8217; living cells to China and other foreign adversaries for genetic engineering and subsequent infusion back into U.S. patients, sometimes <a href="https://www.benzinga.com/general/health-care">without their knowledge or consent</a>.
The <a target="_blank" href="https://www.nih.gov/news-events/news-releases/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic-engineering" rel="noreferrer noopener">move</a> comes amid growing concern over the security and ethics of cross-border biomedical research and the handling of sensitive genetic data.
Mounting evidence has shown that some clinical trials failed to inform participants that their biological samples would be transferred abroad, raising red flags about consent and potential misuse of genetic information by foreign governments.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45982666/fda-introduces-tumor-board-style-reviews-for-faster-drug-decisions" target="_blank" rel="noreferrer noopener">FDA Introduces Tumor Board-Style Reviews For Faster Drug Decisions</a>
The practice became possible after the Biden Administration approved a sweeping exemption in late 2024, enabling U.S. companies to export biological samples for processing abroad, even in trials regulated by the FDA.
While the original intent of a 2024 data security rule was to limit data transfers to countries of concern, the exemption, implemented in April 2025, allowed exceptions even for companies partially owned or influenced by the Chinese Communist Party.
FDA Commissioner Dr. Marty Makary criticized the policy, &#8220;The previous administration turned a blind eye and allowed American DNA to be sent abroad, often without the knowledge or understanding of trial participants.&#8221; He emphasized the need to protect patient privacy and restore confidence in U.S. biomedical research.
As part of its response, the FDA will now require companies involved in such trials to prove full transparency, obtain ethical consent, and ensure domestic processing of biological material. New trials failing to meet these standards will not be allowed to proceed.
The agency is coordinating closely with the National Institutes of Health (NIH) to examine federally funded research for any links to the exemption.
NIH Director Dr. Jay Bhattacharya confirmed the agency is conducting a portfolio-wide review to assess whether any NIH-supported trials were affected.
&#8220;In light of the FDA&#8217;s actions and new information surrounding the Biden Administration&#8217;s egregious policies, the National Institutes of Health is actively reviewing its entire research portfolio to determine whether any federally funded clinical trials utilized the exemption issued under the Biden Administration that allowed American biological materials to be sent abroad for genetic modification, particularly to entities operating in countries of concern,&#8221; Bhattacharya said in a statement on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45326322/trump-appointed-martin-makary-targets-faster-drug-approvals-with-fda-artificial-intelligence-overhaul" target="_blank" rel="noreferrer noopener">Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Health Care

General

CRBU

CRSP

NTLA

SANA

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and lowers the price target from $464 to $460.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $460

Throughout the last three months, 10 analysts have evaluated Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average reflects an increase of 0.62% from the previous average price target of $479.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1750183256_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Vertex Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$420.00</td>
<td>$423.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$423.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$442.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$464.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$515.00</td>
<td>$512.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$503.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$535.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$420.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$567.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Vertex Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>About Vertex Pharmaceuticals</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 2.96%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.85%, the company showcases effective utilization of assets.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $423 to $420.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $420

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an average annual return of 13.76%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.96 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,624.96 today based on a price of $447.67 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749572112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels.
What Happened: Speaking on The Diary of a CEO podcast last week, Wood said the convergence of gene sequencing, artificial intelligence and CRISPR gene editing is beginning to cure diseases previously thought untreatable, and it&#8217;s already generating revenue.
&#8220;This is already beginning to happen,&#8221; Wood said. &#8220;We are able to diagnose cancer with a blood test in Stage 1,&#8221; and even before stage 1 she says, adding that if cancer was discovered in &#8220;Stage 1,&#8221; it can save most people. 
Wood highlighted CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) as key beneficiaries of this shift. The two companies co-developed Casgevy, a therapy now approved to treat sickle cell disease and beta thalassemia with a single dose.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45831309/why-jeff-bezos-might-emerge-as-the-biggest-winner-in-the-trump-musk-feud">Why Jeff Bezos Might Emerge As The Biggest Winner In The Trump-Musk Feud?</a>
&#8220;There's huge demand,&#8221; Wood said, pointing to the severe burden patients suffering from sickle cell disease and beta thalassemia face from repeated hospitalizations. &#8220;Of course they're going to go through a tough regimen, they want to live a more normal life.&#8221;
Casgevy, she says was approved by U.S. and U.K. regulators in late 2023 and is already generating revenue for both firms. Wood believes this marks the beginning of a longer-term transformation in health care economics, where curative, one-time treatments could replace recurring drug regimens, disrupting traditional pharma revenue models.
Wood concluded by saying the she believes these technologies will go up &#8220;more than tenfold in the next five to 10 years,&#8221; adding that &#8220;the opportunities are going to be enormous.&#8221;
Why It Matters: Ark Invest has been a <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">proponent of AI and biologic</a>s for the past several years, having called it a $400 billion opportunity just last year. 
Several other prominent experts and entrepreneurs have <a href="https://www.benzinga.com/general/biotech/23/02/30749615/bill-gates-gets-excited-about-future-of-tech-that-has-revolutionized-health-over-past-decade">espoused similar views</a>. This includes Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) founder Bill Gates, who said that CRISPR techonlogy had already &#8220;revolutionized health over the past decade,&#8221; adding that he was excited to see how it will evolve and intersect with other technologies. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">Year-To-Date Performance</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)</td>
<td class="has-text-align-center" data-align="center">+1.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</td>
<td class="has-text-align-center" data-align="center">+11.03%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td class="has-text-align-center" data-align="center">-4.82%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>)</td>
<td class="has-text-align-center" data-align="center">+7.45%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png" alt="" class="wp-image-942918" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Crispr Therapeutics scores poorly across the board. While it does have a favorable price trend in the short and medium-terms, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here&#8217;s</a> how it compares with Vertex, and other promising biotech stocks. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="World Leading Investing Expert: The Big Shift Is Coming! This Investment Could 15x in 5 Years!" width="500" height="281" src="https://www.youtube.com/embed/ZznpMh0DegE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45831613/collapse-in-immigration-poses-a-bigger-economic-threat-than-trumps-tariffs-warns-deutsche-bank-negative-supply-shock-is-not-good-news-for-a-currency">&#8216;Collapse In Immigration&#8217; Poses A Bigger Economic Threat Than Trump&#8217;s Tariffs, Warns Deutsche Bank: &#8216;Negative Supply Shock Is Not Good News For A Currency&#8217;</a></li>
</ul>
Photo courtesy: T. Schneider / Shutterstock.com

ARKG

ARKK

MSFT

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis -
- Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA&#xAE; –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54266897&amp;newsitemid=20250606362203&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=eb77f3c67389e9e5a8a914fa1115154c">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK&#xAE; (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year's European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy.
During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit including better and more stable lung function, fewer pulmonary exacerbations, better nutritional status and better quality of life. SwCl levels below 30 mmol/L generally demonstrated greater numerical benefit than all other groups, with confidence intervals that overlapped with the ≥30 to &lt;60 mmol/L group.
Vertex also presented the results of a post hoc analysis from the Phase 3 randomized, controlled and open-label trials of ALYFTREK (abstract WS19.04) which suggest treatment with ALYFTREK is associated with improved health-related quality of life outcomes in adolescents and adults, and with improved CF symptoms and general functioning in children aged 6-11 years compared to patients treated with TRIKAFTA.

Vertex Pharma Showcases ALYFTREK's Clinical And Quality Of Life Benefits At European Cystic Fibrosis Conference

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 27.71% since its last report. The company recently reported that it has 4.82 million shares sold short, which is 2.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749049251_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.35%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.30 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,256.99 today based on a price of $445.10 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748466014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

5 Health Care Stocks Whale Activity In Today's Session

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.54 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $3,175.99 today based on a price of $446.03 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747779320_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

The Board of Directors of Vertex Pharmaceuticals Incorporated (the "Company") has authorized an additional program to repurchase up to $4.0 billion of the Company's common stock (the "2025 Repurchase Program"). The 2025 Repurchase Program does not have an expiration date and can be discontinued at any time. Under the 2025 Repurchase Program, the Company may repurchase stock from time to time, subject to general business and market conditions and other investment opportunities, on the open market or through privately negotiated transactions, including through Rule 10b5-1 plans.
 &nbsp;
In 2023, the Company's Board of Directors authorized a program to repurchase up to $3.0 billion of the Company's common stock (the "2023 Repurchase Program"). As of May 16, 2025, the Company had approximately $775 million remaining authorization available under the 2023 Repurchase Program. Between the 2025 Repurchase Program and the 2023 Repurchase Program, the Company is authorized to repurchase up to $4.775 billion of the Company's common stock.

Buybacks

Vertex Pharmaceuticals Authorizes $4B Stock Repurchase Program

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 6.12% on an annualized basis producing an average annual return of 17.82%. Currently, Vertex Pharmaceuticals has a market capitalization of $112.51 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on a price of $438.12 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747152920_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/09/final-trades-vertex-pharma-palantir-wynn-resorts-and-microsoft.html">Halftime Report Final Trades</a>,&#8221; Brenda Vingiello, Chief Investment Officer of Sand Hill Global Advisors, picked Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) as her final trade.
Wynn Resorts, on May 6, reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.19 per share. The company reported quarterly sales of $1.7 billion which missed the analyst consensus estimate of $1.74 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Stephen Weiss, Chief Investment Officer of Short Hills Capital Partners, named Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), <a href="https://in.benzinga.com/general/biotech/25/05/45208824/vertex-pharmaceuticals-stock-falls-on-q1-earnings-revenue-miss-company-raises-low-end-of-fy25-revenue-guidance">saying it will bounce</a>.
On the earnings front, Vertex reported first-quarter adjusted earnings per share of $4.06 on May 5, down from $4.76 a year ago and missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Kevin Simpson, Capital Wealth Planning CIO, said Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) reported impressive earnings, with revenue gaining 39% in the first quarter.
Citigroup analyst Tyler Radke raised the price target on the stock from $110 to $115 on May 8, supporting her view.
Jim Lebenthal of Cerity Partners, named Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as his final trade.
On April 30, Microsoft reported stronger-than-expected financial results for the third quarter and also issued strong revenue guidance.
Price Action:
<ul class="wp-block-list">
<li>Vertex Pharmaceuticals shares fell 1.1% to close at $424.99 on Friday.</li>
<li>Palantir Technologies shares slipped 1.6% to settle at $117.30 during Friday's session.</li>
<li>Wynn Resorts shares rose 1.6% to close at $87.93 on Friday.</li>
<li>Microsoft shares climbed 0.1% to settle at $438.73.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a></li>
</ul>

Media

PLTR

WYNN

Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares tumbled 15.40% after the <a href="https://www.benzinga.com//node/45275849" target="_blank" rel="noreferrer noopener">company reported first-quarter results</a>.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) shares dipped 15.20% after it reported lower-than-expected first-quarter 2025 earnings, and analysts <a href="https://www.benzinga.com//node/45236530" target="_blank" rel="noreferrer noopener">revised the price forecasts</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 14.12%.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares dived 12.96%.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 12.85%. The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended <a href="https://www.benzinga.com//node/45234032" target="_blank" rel="noreferrer noopener">for American consumers and patients</a>.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) shares dived 11.97% after reporting <a href="https://www.benzinga.com//node/45299460" target="_blank" rel="noreferrer noopener">first-quarter results</a>, but issuing a weaker-than-expected Q2 sales outlook.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock was down 11.60% after the <a href="https://www.benzinga.com//node/45205736" target="_blank" rel="noreferrer noopener">company reported quarterly results</a>. Analysts revised the price <a href="https://www.benzinga.com/quote/bntx/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock declined 11.33% after the company reported third-quarter results and <a href="https://www.benzinga.com//node/45322588" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
<li>FNF Group of Fidelity National Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) stock declined 10.98% after the company <a href="https://www.benzinga.com//node/45266700" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock fell 10.81% last week in reaction to an executive order from the Trump administration to boost <a href="https://www.benzinga.com//node/45233995" target="_blank" rel="noreferrer noopener">domestic drug manufacturing</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock declined 10.57% after the company reported its<a href="https://www.benzinga.com//node/45300096" target="_blank" rel="noreferrer noopener"> first-quarter financial results</a>. Analysts revised the stock&#8217;s price forecast.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares decreased 10.52% after announcing downbeat first-quarter sales, and <a href="https://www.benzinga.com//node/45264549" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
</ol>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$76.00</td>
<td>$46.3K</td>
<td>2.0K</td>
<td>4.3K</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$105.00</td>
<td>$32.6K</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$75.00</td>
<td>$45.3K</td>
<td>334</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$32.1K</td>
<td>27</td>
<td>908</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$192.50</td>
<td>$25.0K</td>
<td>618</td>
<td>726</td>
</tr>
<tr>
<td>GH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$22.50</td>
<td>$46.7K</td>
<td>219</td>
<td>73</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$500.00</td>
<td>$43.1K</td>
<td>494</td>
<td>41</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$790.00</td>
<td>$45.0K</td>
<td>160</td>
<td>12</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$490.00</td>
<td>$32.8K</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$280.00</td>
<td>$35.8K</td>
<td>1.7K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 7 day(s) on May 16, 2025. This event was a transfer of 315 contract(s) at a $76.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.3K, with a price of $147.0 per contract. There were 2065 open contracts at this strike prior to today, and today 4318 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with neutral sentiment. It expires in 133 day(s) on September 19, 2025. Parties traded 152 contract(s) at a $105.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $215.0 per contract. There were 275 open contracts at this strike prior to today, and today 1355 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 27 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $45.3K, with a price of $1680.0 per contract. There were 334 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option trade with bullish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 6 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.1K, with a price of $5351.0 per contract. There were 27 open contracts at this strike prior to today, and today 908 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 16, 2025. Parties traded 137 contract(s) at a $192.50 strike. This particular call needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $183.0 per contract. There were 618 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• For GH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), we notice a call option sweep that happens to be bullish, expiring in 224 day(s) on December 19, 2025. This event was a transfer of 22 contract(s) at a $22.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $46.7K, with a price of $2123.0 per contract. There were 219 open contracts at this strike prior to today, and today 73 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with neutral sentiment. It expires in 769 day(s) on June 17, 2027. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $43.1K, with a price of $4315.0 per contract. There were 494 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bullish sentiment. It expires in 98 day(s) on August 15, 2025. Parties traded 10 contract(s) at a $790.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $4500.0 per contract. There were 160 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bearish, expiring in 161 day(s) on October 17, 2025. This event was a transfer of 5 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $6569.0 per contract. There were 21 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bullish, expiring in 616 day(s) on January 15, 2027. This event was a transfer of 4 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $35.8K, with a price of $8950.0 per contract. There were 1706 open contracts at this strike prior to today, and today 4 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ILMN

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

CNBC Halftime Report Final Trades: Vertex Pharmaceuticals, Palantir Technologies, Wynn Resorts, Microsoft Corporation

Live On CNBC, Kevin Simpson Announces Sold Vertex Pharmaceuticals

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported lower-than-expected first-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45206073/vertex-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">quarter 2025 earnings</a>.
Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $4.32</a>.
The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Total revenue&nbsp;increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio&nbsp;and an early contribution from the&nbsp;U.S.&nbsp;launch of Alyftrek.
<ul>
<li>In the U.S., total revenue increased 9% to $1.66 billion due to continued strong patient demand and higher net realized pricing.</li>
<li>Outside the U.S., total revenue decreased 5% to $1.11 billion, as strong patient demand in established and newer markets was offset by the expected revenue decline in Russia, where Vertex is experiencing a violation of its intellectual property rights. </li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44569612/vertex-discontinues-development-of-type-1-diabetes-candidate-after-disappointing-data" rel="noreferrer noopener">Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data</a>
&#8220;Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&amp;D pipeline. We continued to expand our leadership in CF and build global momentum for CASGEVY, and we launched JOURNAVX in moderate-to-severe acute pain,&#8221; said&nbsp;Reshma Kewalramani, CEO and President of&nbsp;Vertex. &#8220;With multiple programs in pivotal development including povetacicept, which continues to make rapid progress in achieving its potential as a pipeline-in-a-product, and additional programs in early and mid-stage development,&nbsp;Vertex&nbsp;is poised to continue to deliver value for years to come.&#8221;
Guidance: Vertex raised the low end of total revenue guidance by&nbsp;$100 million&nbsp;to&nbsp;$11.85&nbsp;billion-$12 billion from $11.75 billion-$12 billion, compared to the consensus of $11.97 billion.
The guidance also includes an immaterial cost impact from tariffs in 2025 based on currently known tariff rates and regulations.
Vertex&nbsp;has temporarily paused the multiple ascending dose portion of the Phase 1/2 study of VX-522, a nebulized CFTR mRNA therapy, to assess a tolerability issue.
William Blair writes, &#8220;While the pause is unfortunate, we believe that the decision to pause the study rather than discontinue it suggests that, beyond the tolerability issue, management is encouraged by the data generated to date given it is open-label.&#8221;
Analyst Myles Minter writes, &#8220;While there was a slight miss on the top line leading to shares trading off 3% in the aftermarket, management raised the lower end of total revenue guidance, suggesting Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized Trikafta copy in Russia. We would be buyers on weakness here as the CF franchise still represents one of the most stable long-term growth franchises with a competitive moat in the biotech sector.&#8221;
Analyst reactions:
<ul>
<li>Leerink Partners downgrades Vertex from Outperform to Market Perform and lowers the <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $550 to $503</a>.</li>
<li>Needham reiterates Vertex Pharmaceuticals from Hold to Hold.</li>
<li>JP Morgan maintains Vertex with an Overweight rating, raising the price target from $512 to $515.</li>
</ul>
Price Action: VRTX stock closed lower by 9.91% at $450.61&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

Press Releases

Vertex to Participate in Upcoming March Investor Conferences

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

Vertex to Announce First Quarter 2025 Financial Results on May 5th

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex Reports First Quarter 2025 Financial Results

Vertex to Participate in Upcoming Investor Conferences

NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

ALNY

COEP

MRNA

NNVC

RPRX

Morgan Stanley

RBC Capital

Scotiabank

JP Morgan

Cantor Fitzgerald

Vertex Pharm

Untitled design - 2025-03-31T165341.547

TNXP

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

지난주 가장 저조한 성과를 기록한 대형주는 다음과 같다.
<ol class="wp-block-list">
<li>아겐스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) 주가는 <a href="https://www.benzinga.com//node/45275849" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 15.40% 급락했다.</li>
<li>버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) 주가는 예상을 하회하는 2025년 1분기 수익을 발표한 후 15.20% 하락했으며, 애널리스트들은 <a href="https://www.benzinga.com//node/45236530" target="_blank" rel="noreferrer noopener">목표주가를 수정</a>했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) 주가는 14.12% 하락했다.</li>
<li>메이크마이트립(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) 주가는 12.96% 급락했다.</li>
<li>리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) 주가는 12.85% 하락했다. 미국 식품의약국(FDA)은 <a href="https://www.benzinga.com//node/45234032" target="_blank" rel="noreferrer noopener">미국 소비자와 환자를 위한 식품, 필수 의약품 및 기타 의약품을 생산하는 외국 제조 시설의 무작위 검사를 확대할 의사를 밝혔다</a>.</li>
<li>로켓 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) 주가는 <a href="https://www.benzinga.com//node/45299460" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 11.97% 급락했으며, 예상보다 낮은 2분기 매출 전망을 제시했다.</li>
<li>바이온엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) 주가는 <a href="https://www.benzinga.com//node/45205736" target="_blank" rel="noreferrer noopener">분기 실적을 발표</a>한 후 11.60% 하락했으며, 애널리스트들은 <a href="https://www.benzinga.com/quote/bntx/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 수정</a>했다.</li>
<li>어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) 주가는 11.33% 하락했으며, 회사는 <a href="https://www.benzinga.com//node/45322588" target="_blank" rel="noreferrer noopener">3분기 실적을 발표하고 목표주가를 수정</a>했다.</li>
<li>FNF 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) 주가는 <a href="https://www.benzinga.com//node/45266700" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 10.98% 하락했다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) 주가는 지난 주 트럼프 행정부의 <a href="https://www.benzinga.com//node/45233995" target="_blank" rel="noreferrer noopener">국내 의약품 제조 강화를 위한 행정명령</a>에 반응하여 10.81% 하락했다.</li>
<li>오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) 주가는 <a href="https://www.benzinga.com//node/45300096" target="_blank" rel="noreferrer noopener">1분기 재무 실적을 발표</a>한 후 10.57% 하락했으며 애널리스트들은 목표주가를 수정했다.</li>
<li>도어대시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) 주가는 부진한 1분기 매출 발표 후 10.52% 하락했으며, <a href="https://www.benzinga.com//node/45264549" target="_blank" rel="noreferrer noopener">애널리스트들은 목표주가를 수정</a>했다.</li>
</ol>
사진 제공: Jonathan Weiss via Shutterstock

2025년 2분기가 시작되면서 미국 증시는 계속 하락하고 있지만, S&amp;P 500 주식 중 일부는 <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noopener">도널드 트럼프의 관세 정책</a>으로 촉발된 혼란에도 거의 영향을 받지 않고 있다.
1분기에 눈에 띄는 상승세를 보인 종목들은 2분기 첫 주까지 상승세를 유지하면서, 관세와 실적 전망 둔화 압력으로 시장이 전반적으로 침체된 가운데서도 회복세를 보이고 있다.
2025년 1분기에 가장 성과가 좋았던 S&amp;P 500 주식 다섯 종목은 CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), 필립모리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), 센코라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), 그리고 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)이며, 이들은 최근 며칠 동안 단지 미미한 하락만 겪었다. 무역 긴장과 경기 침체에 대한 우려로 S&amp;P 500 지수가 10% 급락한 것과는 대조적이다.
<h3 class="wp-block-heading">시장 약세 속 1분기 스타 종목</h3>
<ul>
<li>CVS 헬스는 1분기에 50.9% 급등하며 1975년 이후 최고의 분기 성과를 기록했다. S&amp;P 500이 4월 첫 주에 10% 하락한 반면, CVS 헬스는 2분기에 단지 5% 하락했다.</li>
<li>필립모리스는 지난 분기에 31.9% 급증하며 여러 기록적인 고점을 찍었고, 2008년 상장 이후 두 번째로 좋은 분기를 기록했다. 필립모리스는 현재 4.8% 하락했다.</li>
<li>뉴몬트는 금의 호황을 타고 19% 상승한 금 가격 덕분에 29.7% 급등하며 2020년 초 이후 가장 강력한 3개월 성과를 올렸다. 뉴몬트는 2분기에 7.2% 하락했지만, 광범위한 시장보다 더 완만한 하락세를 보였다.</li>
<li>센코라(이전의 아메리소스버겐(AmerisourceBergen))는 23.8% 상승했으며, 이번 달에는 0.2% 상승하며 관세로 인한 하락세를 피했다.</li>
<li>버텍스 파마슈티컬스는 1분기에 21% 상승했으며, 2분기에는 보합세를 보이며 생명공학 분야에서 인상적인 안정성을 보여주고 있다.</li>
</ul>
<h3 class="wp-block-heading">하지만 추가 상승 여지가 있을까?</h3>
인상적인 성과에도 불구하고, 향후 상승폭은 제한적일 수 있다. 애널리스트 컨센서스는 뉴몬트와 CVS 헬스만 각각 25.8%와 13.2%의 잠재적 상승 여지를 나타낸다.
다른 종목들은 앞으로의 전망이 그리 매력적이지 않다. 이미 평가가 높아지고 있으며, 무역 긴장 재발과 기업 이익률 약화 신호 등 거시경제적 위험이 증가하고 있어, 애널리스트들이 향후 몇 주 내에 전망을 하향 조정하기 시작하면 추가 상승 가능성이 빠르게 사라질 수 있다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>회사</th>
<th>2025년 1분기 주가 변동</th>
<th>연초 대비 주가 변동</th>
<th>목표주가 중앙값 대비 상승 여지</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS 헬스 (CVS)</td>
<td>+50.9%</td>
<td>+43.71%</td>
<td>+13.16%</td>
</tr>
<tr>
<td>필립모리스 (PM)</td>
<td>+31.9%</td>
<td>+26.02%</td>
<td>+2.86%</td>
</tr>
<tr>
<td>뉴몬트 코퍼레이션 (NEM)</td>
<td>+29.7%</td>
<td>+21.77%</td>
<td>+25.77%</td>
</tr>
<tr>
<td>센코라 (COR)</td>
<td>+23.8%</td>
<td>+23.78%</td>
<td>+0.68%</td>
</tr>
<tr>
<td>버텍스 제약 (VRTX)</td>
<td>+21.0%</td>
<td>+19.20%</td>
<td>+6.66%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">2025년 4월 7일 기준 데이터</figcaption></figure>
이미지: 미드저니 통해 인공지능으로 생성
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

S&P 500 종목 중 2025년 1분기에 강세 보인 5개 주식...랠리 지속될까?

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다.
<ul>
<li>맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 오늘 개장 전 실적을 발표할 예정이며 매출 64억 4천만 달러, 주당순이익 2.84달러가 예상된다. 주가는 시간외 거래에서 0.02% 하락한 294.25달러를 기록했다.</li>
<li>온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>): 오늘 개장 전 실적을 발표할 예정이며, 매출 17억 6천만 달러, 주당순이익 97센트가 예상된다. 주가는 시간외 거래에서 0.5% 하락한 51.00달러를 기록했다.</li>
<li>복스 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOXX#NASDAQ">VOXX</a>): 3분기에 주당 1.90의 손실을 기록했으며, 지난해에는 주당 8센트의 이익을 기록했다. 매출은 1억 3,526만 달러에서 1억 5,517만 달러로 감소했다. 주가는 시간외 거래에서 0.3% 하락한 7.38달러를 기록했다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>로크웰 오토메이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>): 오늘 개장 전 실적을 발표할 예정이며 주당순이익 1.59달러, 매출 18억 8천만 달러로 예상된다. 주가는 시간외 거래에서 0.4% 하락한 267.35달러를 기록했다.</li>
<li>버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): 오늘 장 마감 후 실적을 발표할 에정이며 주당순이익 4.03달러, 매출 27억 8천만 달러로 예상된다. 주식은 금요일에 2.5% 하락한 469.32달러로 마감했다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)는 주가가 악성 <a href="https://kr.benzinga.com/?s=%EB%8D%B0%EC%8A%A4+%ED%81%AC%EB%A1%9C%EC%8A%A4" target="_blank" rel="noopener">데스 크로스</a>(Death Cross)를 형성하면서 하락세 기술 신호를 받고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-722205" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM-300x231.png 300w" alt="" width="628" height="483" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
이는 50일 이동 평균선이 200일 이동 평균선 아래로 떨어질 때 발생하며, 보통 장기적인 하락세의 전조로 여겨진다. 버텍스의 경우, 기술적 문제는 더 넓은 하락세와 일치하며, 지난 6개월 동안 15% 하락했고, 지난 한 달 동안에는 거의 14% 하락했다.
또한 읽어보세요: <a href="https://www.benzinga.com/insights/news/25/01/42851189/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-this-much-today">20년 전에 이 주식에 1,000달러를 투자했다면 오늘 이 정도를 가졌을 것입니다.</a>
<h2 class="wp-block-heading">낙천적 낭만이 통증 완화제 실패로 가려지다</h2>
버텍스는 매출의 90% 이상을 낙관적으로 나타내는 낭만적 약물 프랜차이즈에서 얻고 있지만, 투자자들의 회의론을 뚫고 나갈 수 없었다.
2024년에는 CASGEVY를 통해 최초의 유전자 편집 기반 겸혈병 치료제로 주목을 받았다. 인사이더 머니에 <a href="https://www.insidermonkey.com/blog/jim-cramers-take-on-vertex-pharmaceuticals-vrtx-bold-predictions-for-the-future-1417241/">따르면</a>, 그러나 12월에는 기대를 모았던 비중독성 통증 완화제가 임상 시험 목표를 달성하지 못하면서 주가가 11% 하락했다.
<h2 class="wp-block-heading">VRTX 주식 차트는 낙관적이지 않다</h2>
VRTX 주식은 여러 매도 신호를 나타내고 있다:
<ul>
<li>이동 평균: 월요일 종가인 VRTX 주식이 $402.49로 50일($456.92) 및 200일($457.35) 이동 평균선 아래에 있으며, 이는 데스 크로스를 강화한다.</li>
<li>이동평균 수렴 발산 지표(MACD): -17.17의 부정적인 수치는 강한 하락 모멘텀을 나타낸다.</li>
<li>상대 강도 지수(RSI): 32.59로 주식이 과매도 수준에 가까워지고 있지만, 아직 반전 구역에 도달하지는 않았다.</li>
</ul>
<h2 class="wp-block-heading">크레이머의 호출이 압박을 받다</h2>
지난 8월, 짐 크레이머는 버텍스를 바이오텍에서 유망한 기업으로 찬양하며, 낙관적으로 나타내는 낭만적 약물과 <a href="https://www.benzinga.com/24/08/40624639/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics" target="_blank" rel="noopener" data-google-interstitial="false">통증 관리</a> 분야에서의 혁신적인 작업을 강조했다.
그 이후로 주가는 거의 18% 하락했으며, 이는 바이오텍 부문에 자주 발생하는 변동성을 반영한다.
버텍스의 기술적 및 기본적 문제는 투자자들이 반등을 보기 위해 인내가 필요할 수 있음을 시사한다.
주가 움직임: 버텍스의 주식은 화요일 1.45% 상승한 $408.32에 마감되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst">버텍스 파마슈티컬스: 알리프트렉은 상단 및 하단 라인에 대한 &#8216;부가적 기회&#8217;입니다. 낙관적인 분석가가 말합니다.</a></li>
</ul>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Technicals

버텍스의 주가는 데스 크로스를 형성한 약세 차트와 힘겨루기 중

이들 11개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식이 20.52% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42613036" target="_blank" rel="noreferrer noopener">REDEFINE 1의 3상 시험</a> 주요 결과를 발표한 후 발생한 일이다.
2. 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)의 주식은 14.33% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">스즈트리진(</a><a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Suzetrigine</a><a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">)의 2상 연구 결과</a>를 발표한 후 발생한 일이다.
3. XPO(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>)의 주식이 13.47% 하락했다.
4. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식이 13.33% 하락했다. 이는 회사가 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A7%84%EC%9E%85-%EB%AA%87-%EB%8B%AC-%EB%A7%8C%EC%97%90-%EB%82%98%EC%8A%A4%EB%8B%A5-100%EC%97%90%EC%84%9C-%EC%A0%9C%EC%99%B8-%EC%9C%84%EA%B8%B0%EC%97%90-%EC%B2%98%ED%95%9C-%EC%8A%88%ED%8D%BC/" target="_blank" rel="noopener">나스닥 100 지수에서 제외될 예정</a>이라고 발표한 후 발생한 일이다.
5. 누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)의 주식이 13.07% 급락했다. 이는 새로운 정부 재정 지출 패키지와 지난주 중앙은행 금리 인상이 글로벌 투자자 신뢰를 약화시키고 국가의 적자에 대한 우려를 불러일으킬 수 있기 때문이다.
6. Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주식이 13.01% 하락했다. 이는 퀄컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)과의 <a href="https://www.benzinga.com//node/42538739" target="_blank" rel="noreferrer noopener">지속적인 법적 분쟁</a>으로 인한 약세 때문으로 보인다.
7. 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식이 12.08% 하락했다. 이는 회사가 혼재된 실적 결과와 현재 분기에 대한 부진한 가이던스를 발표한 후 발생한 일이다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/42594359" target="_blank" rel="noreferrer noopener">가격 전망을 하향 조정</a>했다.
8. 페이컴 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>)의 주식이 11.63% 하락했다. 이는 연준의 금리 결정으로 소프트웨어 주식이 매도세를 경험한 결과이다.
9. 신타스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>)의 주식이 11.50% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42588404" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ctas/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>한 결과이다.
10. 워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주식이 <a href="https://www.benzinga.com//node/42603589" target="_blank" rel="noreferrer noopener">11.43% 하락</a>했다.
11. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식이 11.20% 하락했다. 이는 씨티그룹이 주가 전망을 <a href="https://www.benzinga.com/quote/mndy/analyst-ratings" target="_blank" rel="noreferrer noopener">338달러에서 302달러로 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EB%B0%94-%EB%A6%AC-%EC%98%A4%ED%86%A0-%EB%B0%8F-%EB%8B%A4%EB%8D%B4-%EB%A0%88%EC%8A%A4%ED%86%A0%EB%9E%91%EC%9D%B4-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CTAS

CVNA

MNDY

MSTR

PAYC

QCOM

SMCI

노보 노디스크, 버텍스 및 Arm은 지난주 최악의 성과를 보인 11개 대형주 중 일부 (12월 16-20일)

전 대통령 도널드 트럼프는 이전에 백악관에서 4년 동안 재직한 경험이 있기 때문에, 그가 <a href="https://www.benzinga.com/topic/2024-election">2024년 대선</a>에서 승리하여 두 번째 임기를 수행할 경우 어떤 주식과 섹터가 혜택을 볼 수 있을지 투자자들이 파악하는 데 도움이 될 수 있다.
트럼프가 백악관에 처음 입성한 2017년에 가장 잘 수행된 주식들을 살펴보겠다.
2017년 최고의 주식들: 주식 시장은 2017년에 인상적인 상승세를 보였으며, 이는 대통령의 <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">첫 해에 가장 좋은 성과 중 하나</a>였다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500은 2017년에 21.7% 상승했는데, 이는 2016년 +12.0% 상승에 비해 인상적인 상승률이다. 역사적으로 대통령 선거 연도가 다른 연도에 비해 뛰어난 성과를 거두었기 때문이다.
트럼프가 2024년에 재선될 가능성이 있는 만큼, 2017년 S&amp;P 500에서 가장 성과가 좋았던 10개 주식을 살펴보겠다. 이는 이전에 <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">마켓워치</a>에 의해 보도된 내용다.
<ol>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, 유틸리티</li>
<li>얼라인 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, 헬스케어</li>
<li>버텍스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, 헬스케어</li>
<li>윈 리조트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, 소비재</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, 산업재</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, 기술</li>
<li>D.R. 호튼 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, 소비재, 주택 건설업체</li>
<li>페이팔 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, 기술</li>
<li>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, 기술</li>
<li>풀테 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, 소비재, 주택 건설업체</li>
</ol>
2017년의 상위 10개 주식들은 트럼프가 대통령인 것과 관련이 없는 이유로 상승세를 보였을 가능성이 있지만, 몇 가지 공통된 주제가 있으며 전 대통령과의 잠재적인 연결고리도 있다.
결과적으로 헬스케어, 소비재 및 기술 주식들이 상위 성과를 보이는 섹터로 나타났다.
특히 마이크론과 엔비디아가 모두 상위 10위 안에 든 점은 주목할 만한 사항으로, 이는 트럼프 대통령 하에서 반도체 섹터에 긍정적인 영향을 미칠 수 있다.
또한 두 개의 주택 건설사가 2017년 가장 성과가 좋았던 주식 중 두 개로 선정된 것은 중요한 추세일 수 있다. 주택 건설업체는 현재 부통령인 카멀라 해리스가 승리할 경우 주목할만한 섹터로 여겨져 왔으며, 트럼프는 중산층을 위한 <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">주택 건설 확대</a> 공약을 내세우고 있다.
알고 계셨나요?
<ul>
<li>의회가 막대한 투자를 하고 있습니다. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">2024년 선거를 앞두고 그들이 매입하고 매각한 것에 대한 팁을 쉽게 알아보세요.</a></li>
</ul>
중요한 이유 (Why It&#8217;s Important): 과거의 결과가 미래의 결과를 보장하지는 않지만, 때때로 시장 추세는 패턴과 신호를 보여줄 수 있다.
2017년의 상위 성과 주식을 기반으로 볼 때, 트럼프가 2024년 대선에서 승리할 경우 투자자들은 헬스케어, 유틸리티, 반도체 및 주택 건설업체에 대한 <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">노출을 준비</a>할 수 있다.
2024년 대선까지 2주도 채 남지 않았기 때문에, 투자자들은 트럼프나 해리스의 승리를 기준으로 포트폴리오를 조정하고 있을 가능성이 높다. 예측되는 근소한 선거 결과를 감안할 때, 투자자들은 두 후보 중 어느 쪽이 당선되더라도 혜택을 받을 수 있는 섹터를 살펴보는 것이 좋다.
프리덤 캐피털 마켓(Freedom Capital Markets)의 수석 글로벌 전략가 제이 우즈(Jay Woods)는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">2024년 대선에서 트럼프나 해리스 승리 여부와 관계없이 주목해야 할 섹터와 주식</a>을 벤징가와 공유한 바 있다.
우즈는 방산 주식과 사이버 보안 주식을 2024년 대선 전 주목해야 할 두 개의 주요 섹터로 명명했다.
&#8220;이 섹터를 면밀히 주시해야 한다고 생각한다&#8221;라고 방산 섹터에 대해 우즈가 말했다.
우즈는 방산 주식이 지정학적 우려와 세계에서 발생하는 여러 문제들로 인해 계속해서 혜택을 받을 수 있다고 언급했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">트럼프가 2024년 대선에서 압승할 경우, 베팅자들은 영국 스포츠북에서 베팅금의 5배, 20배를 받을 수 있다.</a></li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Politics

ALGN

NVDA

PYPL

트럼프 대통령 시기인 2017년 S&P 500에서 가장 우수한 성과를 거둔 10개 주식: 역사가 반복될까?

캐시 우드의 아크 인베스트(Ark Invest)가 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에 대해 중요한 거래를 했다.
아마존 거래: 아크 인베스트는 최근 회사의 성장 궤도에 대한 우려에도 불구하고 아마존 주식 76,505주를 매수했다. 이 거래는 아크의 주력 펀드인 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 실행되었다.
이 조치는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41234873/amazon-stock-downgrade-by-wells-fargo-a-bearish-signal-on-growth-concerns">웰스 파고</a>가 아마존의 주식을 비중확대(Overweight)에서 중립(Equal-Weight)으로 하향 조정한 후 발생했다. 웰스 파고는 성장 둔화와 치열한 경쟁을 이유로 들었다. 이 거래의 가치는 종가 182.72달러를 기준으로 약 1,398만 달러이다.
아마존의 주식은 웰스 파고가 성장 둔화와 경쟁을 이유로 주식을 하향 조정한 후 월요일에 하락했다. 또한 연방 판사가 연방거래위원회(FTC)의 아마존에 대한 반독점 소송이 진행될 수 있도록 허용한 판결로 인해 매도세가 <a href="https://www.benzinga.com/news/24/10/41216248/amazon-stock-is-sliding-monday-whats-going-on">촉발</a>되었다.
로빈후드 거래: 아크 인베스트는 로빈후의 주식 1,421,431주를 세 개의 ETF인 ARKK, ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 및 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>))를 통해 매도했다. 이 결정은 로빈후드가 첫 투자자 데이를 발표하고 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41236863/robinhood-eyes-major-growth-with-new-trading-features-while-coinbase-rides-crypto-s">새로운 거래 기능</a>을 도입한 최근 발표에도 불구하고 이루어졌다. 이 거래의 가치는 종가 25.61달러를 기준으로 약 3,640만 달러이다.
코인베이스 거래: 아크 인베스트는 ARKF ETF를 통해 코인베이스의 주식 12,994주를 매수했다. 이 조치는 코인베이스의 주식이 회사가 <a href="https://www.benzinga.com/news/24/10/41191796/why-coinbase-global-shares-are-trading-higher-today">새로운 유럽 규제 요건에 대응하여 서비스 제공을 조정</a>한다고 발표한 후 급등한 것과 일치한다. 이 거래의 가치는 종가 167.69달러를 기준으로 약 218만 달러이다.
다른 주요 거래:
1. 아크는 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)의 주식 2,365주를 ARKW ETF를 통해 매수했다. 메타 거래는 140만 달러로 평가되었다. 화요일에 메타 주식은 592.89달러로 1.4% 상승 마감했다.
2. 아크 인베스트는 비바 시스템즈(VEEV)와 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) 주식을 ARKG ETF를 통해 매도했다. 대신 리커젼 파마슈티컬스(RXRX)와 10X 지노믹스(TXG) 주식을 매수했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41221351/elon-musks-theory-gains-ground-polymarket-odds-soar-for-nick-szabo-being-named-bitcoin-cre?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">일론 머스크의 이론이 힘을 얻고 있나? HBO 다큐멘터리에서 닉 사보가 비트코인 창작자 사토시 나카모토로 지명될 가능성이 급등</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ETFs

AMZN

ARKF

ARKW

COIN

HOOD

아크 인베스트 거래: 아마존 주식 $1,400만 매수, 로빈후드 $3,600만 매도, 코인베이스와 메타 매수

전설적인 수학자이자 전 국가안보국(NSA) 암호 해독자인 짐 사이먼스(Jim Simons)가 설립한 헤지펀드인 르네상스 테크놀로지스(Renaissance Technologies)는 최근 8월 9일 미국 증권거래위원회(SEC)에 제출한 13F의 최신 <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">주요 주식 보유 현황을 공시</a>했다.
무슨 일이 (What Happened): 이 공시 서류는 르네상스를 역사상 가장 성공적인 헤지 펀드 중 하나로 만든 정량적 전략을 반영하여 펀드 포트폴리오의 중요한 변화를 <a href="https://www.sec.gov/Archives/edgar/data/1037389/000103738924000073/xslForm13F_X02/renaissance13Fq22024_holding.xml" target="_blank" rel="noopener">보여</a>준다.
이 중 가장 주목할 만한 기업은 덴마크의 거대 제약회사인 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 시장 가치가 13억 달러로 르네상스 포트폴리오의 2.22%를 차지한다. 주식이 15.03% 감소했음에도 불구하고 노보 노디스크는 여전히 펀드의 최고 보유 주식이다. 노보 노디스크는 비만 치료제 오젬픽(Ozempic)이나 위고비(Wegovy)로 유명하다.
주목할 만한 변화에서 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)는 이 포트폴리오의 1.70%를 차지하며 2위를 차지했다. 그러나 르네상스는 팔란티어 포지션을 16.56% 감소시켜 이 데이터 분석 회사의 전망에 대한 잠재적인 재평가를 예고했다.
AI 및 그래픽 처리 분야의 선두주자인 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 르네상스의 보유 지분이 크게 증가했다. 이 펀드는 엔비디아의 지분을 27.52% 증가시켜 포트폴리오의 1.47%로 세 번째로 큰 위치를 차지했다.
기타 주요 보유 종목으로는 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)와 유나이티드 테라퓨틱스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>)이 있으며, 이는 의료 부문에 대한 르네상스의 관심을 강조한다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 보유 주식이 33.39% 크게 감소하여 현재 포트폴리오의 0.89%를 차지한다. 에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)는 또한 23.11%의 상당한 감소를 경험했으며 이는 시장 가치 5억 1,576만 달러로 르네상스 보유 지분의 0.87%를 차지했다.
놀랍게도 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)은 전체 보유 지분의 0.80%와 시장 가치 4억 7,221만 달러로 9위를 차지하며 이 포트폴리오에서 새로운 포지션으로 등장했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 르네상스가 지분을 14.20% 늘려 상위 10위 안에 들었다. 테슬라는 현재 이 포트폴리오의 0.69%를 차지하며 가치는 4억 594만 달러이다.
이 뉴스가 중요한 이유 (Why It Matters): 이번 13F에서는 최근 사이먼스가 <a href="https://www.benzinga.com/news/large-cap/23/09/34771681/hedge-fund-titan-peter-brown-built-a-large-language-model-35-years-ago-read-what-it-wrote">별세한 이후</a>에 피터 브라운(Peter Brown) CEO가 이끄는 르네상스 테크놀로지스의 투자 전략을 엿볼 수 있다. 이 펀드는 사이먼스가 개척한 접근 방식인 복잡한 수학적 모델과 알고리즘 거래를 지속적으로 활용하여 기존 투자 방식보다 지속적으로 뛰어난 성과를 거두었다.
탁월한 성과로 유명한 르네상스의 메달리온 펀드(Medallion Fund)는 1988년부터 2021년까지 연간 62%(수수료 제외 37%)의 수익률을 달성했다. 이 실적은 수익률 측면에서 워런 버핏을 능가하는 <a href="https://www.benzinga.com/news/24/04/38431687/jim-simons-a-math-professor-became-one-of-the-most-successful-investors-of-all-time-now-he-shares-hi" target="_blank" rel="noopener" data-google-interstitial="false">역대 최고의 투자자 중 한 명</a>으로 사이먼스의 유산을 확고히 했다.
포브스(Forbes)에 따르면 사망 당시 사이먼스의 <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves" target="_blank" rel="noopener" data-google-interstitial="false">순자산</a>은 314억 달러로 추산되었다. 그의 유산은 금융을 넘어 수학과 과학 교육에 대한 자선 활동에 크게 기여하고 있다. 특히 1964년에 사이먼스는 국방 분석 연구소(Institute for Defense Analyses)에서 극비 직위를 맡아 소련 코드와 암호를 해독하는 NSA를 지원했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40435655/warren-buffetts-189b-cash-pile-not-a-sign-of-looming-market-crash-says-fund-manager-everybody-gets-e">워런 버핏의 $1,890억 현금 더미는 다가오는 시장 붕괴의 징후가 아니라고 펀드매니저가 주장: &#8216;모두가 흥분하지만&#8230; 그렇게 큰 숫자는 아니다&#8217;</a></li>
</ul>
Image Via Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움으로 제작되었으며 Benzinga 편집자가 검토하고 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABNB

AVGO

TSLA

UTHR

NSA 암호해독 전문가 짐 사이먼스의 헤지펀드 르네상스의 보유 주식 - 노보 노디스크 등

Comments

Vertex Pharmaceuticals

뉴스

에 대한 최신 뉴스 Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

일요일, 5월 11, 2025

월요일, 4월 07, 2025

월요일, 2월 10, 2025

수요일, 1월 08, 2025

일요일, 12월 22, 2024

월요일, 10월 28, 2024

수요일, 10월 09, 2024

화요일, 8월 20, 2024

뉴스

파트너 / 기고자

벤징가 글로벌